AU2020316519A1 - Methods and agents for treating acute neuroinflammatory injury - Google Patents

Methods and agents for treating acute neuroinflammatory injury Download PDF

Info

Publication number
AU2020316519A1
AU2020316519A1 AU2020316519A AU2020316519A AU2020316519A1 AU 2020316519 A1 AU2020316519 A1 AU 2020316519A1 AU 2020316519 A AU2020316519 A AU 2020316519A AU 2020316519 A AU2020316519 A AU 2020316519A AU 2020316519 A1 AU2020316519 A1 AU 2020316519A1
Authority
AU
Australia
Prior art keywords
antibody
seq
sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020316519A
Other languages
English (en)
Inventor
David T. CROWE
Garry Llewellyn REDLICH
Brian W. ZIEGELAAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Implicit Bioscience Ltd
Original Assignee
Implicit Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902642A external-priority patent/AU2019902642A0/en
Application filed by Implicit Bioscience Ltd filed Critical Implicit Bioscience Ltd
Publication of AU2020316519A1 publication Critical patent/AU2020316519A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2020316519A 2019-07-25 2020-07-24 Methods and agents for treating acute neuroinflammatory injury Pending AU2020316519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902642 2019-07-25
AU2019902642A AU2019902642A0 (en) 2019-07-25 Methods and agents for treating acute neuroinflammatory injury
PCT/US2020/043619 WO2021016601A1 (en) 2019-07-25 2020-07-24 Methods and agents for treating acute neuroinflammatory injury

Publications (1)

Publication Number Publication Date
AU2020316519A1 true AU2020316519A1 (en) 2022-02-24

Family

ID=74192699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020316519A Pending AU2020316519A1 (en) 2019-07-25 2020-07-24 Methods and agents for treating acute neuroinflammatory injury

Country Status (8)

Country Link
US (1) US20220249610A1 (https=)
EP (1) EP4003518A4 (https=)
JP (1) JP2022541646A (https=)
KR (1) KR20220040478A (https=)
CN (1) CN114450068A (https=)
AU (1) AU2020316519A1 (https=)
IL (1) IL290046A (https=)
WO (1) WO2021016601A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144141A1 (en) * 2018-01-22 2019-07-25 UNIVERSITY OF VIRGINIA PATENT FOUNDATION d/b/a UNIVERSITY OF VIRGINIA LICENSING & VENTURE System and method for automated detection of neurological deficits
CN116367858A (zh) * 2020-09-10 2023-06-30 隐式生物科技有限公司 用于治疗心肌梗塞的治疗方法和试剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
CA2609262A1 (en) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
WO2008088902A2 (en) * 2007-01-17 2008-07-24 Yale University Attenuation of the adaptive immune response
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
IL309046B2 (en) * 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2022541646A (ja) 2022-09-26
CN114450068A (zh) 2022-05-06
US20220249610A1 (en) 2022-08-11
IL290046A (en) 2022-03-01
KR20220040478A (ko) 2022-03-30
EP4003518A4 (en) 2023-07-12
WO2021016601A1 (en) 2021-01-28
EP4003518A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
KR20250166355A (ko) 안과 질환의 치료
PT1904104E (pt) Anticorpos sp35 e suas utilizações
CA2676185C (en) Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
JP6863892B2 (ja) 脳卒中を治療又は予防する方法
US20250230228A1 (en) Methods and agents for the treatment of ocular disease
CA2665956A1 (en) Combination treatment for ocular diseases
JP6865581B2 (ja) 神経学的疾患又は神経変性疾患に有用な新規抗体
US20220249610A1 (en) Methods and agents for treating acute neuroinflammatory injury
KR20170016501A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
KR20230066048A (ko) 심근경색증 치료를 위한 치료 방법 및 제제
TW200934791A (en) Improved Nogo-A binding molecules and pharmaceutical use thereof
KR20190039134A (ko) Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도
US9221904B2 (en) Treatment of osteoarthritis using IL-20 antagonists
US20180057590A1 (en) Dicam-specific antibodies and uses thereof
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
RU2849860C1 (ru) Применение связывающих cxcl13 молекул для лечения повреждения периферических нервов
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
CA2944624A1 (en) Treatment of inflammatory pain using il-20 antagonists
TW201906865A (zh) 預防及治療尿失禁之方法
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
WO2024052343A1 (en) Trem-2 agonists for the treatment of marfan syndrome
WO2018200620A1 (en) Use of il-20 antagonists for treating eye diseases
EA040534B1 (ru) Способы увеличения безжировой массы тела с помощью антитела к gdf8 или его антигенсвязывающего фрагмента и тренировок с сопротивлением